SCHEMBL3269692

SCHEMBL3269692

COC(=O)/C(C(C)=O)=C(/C)OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
POLB P06746 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
GAA P10253 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 2/20 0.40
MAPT P10636 2/20 0.40
CYP2C9 P11712 1/20 0.40
DNMT1 P26358 1/20 0.40
CYP2C19 P33261 1/20 0.40
RECQL P46063 1/20 0.40
MGAM O43451 1/20 0.32
SI P14410 1/20 0.32
MGAM2 Q2M2H8 1/20 0.32
TSHR P16473 1/20 0.32
THPO P40225 1/20 0.32
TET2 Q6N021 1/20 0.31
EGLN1 Q9GZT9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14282781 1.00 ALDH1A1 (0.43) ALDH1A1POLBMEN1KMT2AGAA
SCHEMBL3269694 1.00 ALDH1A1 (0.43) ALDH1A1POLBMEN1KMT2AGAA
SCHEMBL9794476 0.88 ALDH1A1 (0.48) ALDH1A1POLBMEN1KMT2AGAA
SCHEMBL26477778 0.85 ALDH1A1 (0.47) ALDH1A1POLBMEN1KMT2AGAA
SCHEMBL455415 0.81 ALDH1A1 (0.42) ALDH1A1POLBMEN1KMT2AGAA
SCHEMBL11549074 0.80 ALDH1A1 (0.46) ALDH1A1POLBMEN1KMT2AGAA
SCHEMBL1085140 0.79 GLO1 (0.47) ALDH1A1GAATDP1KDM4EMAPT
SCHEMBL1085139 0.79 GLO1 (0.47) ALDH1A1GAATDP1KDM4EMAPT
SCHEMBL1085142 0.79 GLO1 (0.47) ALDH1A1GAATDP1KDM4EMAPT
SCHEMBL11979152 0.78 ALDH1A1 (0.43) ALDH1A1POLBMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270875-A1 PYRIMIDINE AMIDE COMPOUNDS GILLESPIE PAUL (US) 2012-10-25 US disclosed
US-20120270875-A1 PYRIMIDINE AMIDE COMPOUNDS GILLESPIE PAUL (US) 2012-10-25 US disclosed
WO-2012123467-A1 PYRIMIDINE AMIDE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-20 WO disclosed
US-7759035-B2 Electrostatic charge image developing toner and image forming method KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2010-07-20 US disclosed
US-7759035-B2 Electrostatic charge image developing toner and image forming method KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2010-07-20 US disclosed
EP-2066674-B1 OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AND THEIR USE AS ANTIVIRAL AGENTS HOFFMANN LA ROCHE (CH) 2010-06-30 EP disclosed
EP-2066674-A1 OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AND THEIR USE AS ANTIVIRAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2009-06-10 EP disclosed
EP-1987036-A1 HETERO-BYCYCLIC ANTIVIRAL COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2008-11-05 EP disclosed
WO-2008034731-A1 OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2008-03-27 WO disclosed
WO-2007093520-A1 HETERO-BYCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2007-08-23 WO disclosed
US-20070191335-A1 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease ROCHE PALO ALTO LLC 2007-08-16 US disclosed
US-20070184375-A1 ELECTROSTATIC CHARGE IMAGE DEVELOPING TONER AND IMAGE FORMING METHOD KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2007-08-09 US disclosed
US-20070184375-A1 ELECTROSTATIC CHARGE IMAGE DEVELOPING TONER AND IMAGE FORMING METHOD KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2007-08-09 US disclosed
US-7161024-B2 Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters SCHERING CORPORATION (US) 2007-01-09 US disclosed
US-7161024-B2 Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters SCHERING CORPORATION (US) 2007-01-09 US disclosed
EP-1644313-A2 PROCESS FOR THE PREPARATION AND PURIFICATION OF 2-(ALKOXYALKYLIDENE)-3-KETOALKANOIC ACID ESTERS FROM 3-KETOALKANOIC ACID ESTERS SCHERING CORPORATION (US) 2006-04-12 EP disclosed
US-20050027140-A1 Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters SCHERING CORPORATION 2005-02-03 US disclosed
WO-2005007608-A2 PROCESS FOR THE PREPARATION AND PURIFICATION OF 2-(ALKOXYALKYLIDENE)-3-KETOALKANOIC ACID ESTERS FROM 3-KETOALKANOIC ACID ESTERS SCHERING CORPORATION (US) 2005-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050027140-A1 Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters ACKR3, CCR5, CCRL2 ALDH1A1 437/4885POLB 3869/4885MEN1 4667/4885
US-20120270875-A1 PYRIMIDINE AMIDE COMPOUNDS UMPS, TYMS, DPYD ALDH1A1 258/4885POLB 147/4885MEN1 4776/4885
US-20070191335-A1 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease CCR5, CXCR1, CXCR3 ALDH1A1 1971/4885POLB 2402/4885MEN1 4575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.